Mankind Pharma board approves raising of ₹10,000 cr via private placement
Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26
Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26
The restrictions have been imposed after SEBI observed that regulatory norms were violated in the public issues of NCDs during the year 2023
Parent Vedanta Resources gets board nod to postpone maturity of $3.2 bn in outstanding corporate bonds.
The issue comprises 2 crore non‐convertible debentures of face value of ₹1,000 each, aggregating up to ₹2,000 crore.
The public issue comprises a base issue size of up to ₹250 crore and a green shoe option of up to ₹250 crore.
The board of PNB Housing Finance has approved the issuance of non-convertible debentures aggregating up to ₹5,000 crore on a private placement basis.
The Blackstone-backed REIT intends to use debt capital to refinance bank loans at Special Purpose Vehicle level.
India had 26,42,038 persons undergoing treatment for diabetes as on March 2023.
In February this year, HDFC raised ₹25,000 crore through bonds, which is touted to be the country's largest-ever rupee bond issuance.
Tata Steel to raise ₹2,150 crore via NCDs, which will be the second bond sale in the last five months.